Abstract
OPINION article Front. Oncol., 31 October 2012 | https://doi.org/10.3389/fonc.2012.00155
Highlights
A number of cancers can follow an indolent clinical course, even when the disease is at an advanced stage
Metastatic renal cell carcinoma (RCC) was considered refractory to systemic therapy for many years, but there are seven so called “targeted” agents approved for this condition, which target the critical vascular endothelial growth factor (VEGF) and mammalian target of rapamycin pathways, leading to inhibition of angiogenesis and cell survival and proliferation
All seven drugs have been shown in randomized clinical trials to significantly improve clinical outcomes for patients with Metastatic RCC (mRCC), but they are non-curative and associated in general with moderate toxicity
Summary
A number of cancers can follow an indolent clinical course, even when the disease is at an advanced stage. Prospective evidence for an initial observational strategy in other solid tumor types is limited, even though it is common in clinical practice. It is well recognized that a subgroup of patients with advanced RCC has slowly progressive metastatic disease over a number of years.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
